{"entity":{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","aka":[],"tldr":"Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.","summary":"Aktis Oncology, based in Boston and listed as AKTS, is a miniprotein alpha-radiopharmaceutical company whose IPO, closed on 12 January 2026 for about 365 million dollars, was the first biotech IPO of the year and funds actinium-225 programmes against Nectin-4 and B7-H3. Its lead, 225Ac-AKY-1189 against Nectin-4, is in a US phase 1b; 225Ac-AKY-2519 against B7-H3 has an IND planned for the first half of 2026 after diagnostic imaging and dosimetry studies; an in-house cGMP radiopharmaceutical facility is due in the second half of 2026; and large pharma investors back it. OnCo links it to bladder, small-cell lung and prostate cancer, to targeted alpha therapy and alpha-emitter nanogenerators, and to Nectin-4 and B7-H3 as targets. Whether miniproteins can deliver alpha emitters safely is the open question. The targeted alpha therapy page carries the field.","asOf":"2026-09-04","links":[{"label":"IPO coverage","url":"https://www.fiercebiotech.com/biotech/1st-biotech-ipo-2026-sees-aktis-bring-318m-upsized-offering"}],"tags":["frontier"],"related":["src-fierce-biotech"],"cancers":["urothelial","sclc","prostate"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy"],"targets":["nectin4","b7h3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"radiopharma","website":"https://www.aktisoncology.com","ticker":"AKTS","investors":[],"funding":[]},"route":"/companies/aktis-oncology/","neighbours":{"collection":[{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}],"company":[{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/"},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/"}]}}